Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

PanTher receives ethics approval to initiate phase I study of PTM-101 in Australia

Aug. 5, 2021

Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies

Aug. 5, 2021

FDA clears IND for phase Ib study of camsirubicin in advanced soft tissue sarcoma

Aug. 4, 2021

U.S. phase II dosing begins with LUT-014 to reduce EGFR inhibitor-induced acneiform lesions

Aug. 4, 2021

CytomX Therapeutics describes auristatin-related compounds

Aug. 4, 2021

Cyclin C controls responses to PARP inhibitor treatment in BRCA2-deficient cells

Aug. 4, 2021

Dosing underway in phase I/II study of KRAS G12C inhibitor JAB-21822

Aug. 3, 2021

Ascentage Pharma discovers mutant GTPase KRAS inhibitors

Aug. 3, 2021

New CDK and TRK inhibitors identified at Hangzhou Innogate Pharma

Aug. 3, 2021

Hovione Scientia describes ligand drug conjugates including BET inhibitors

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...